Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

FLORIDA PAIN RELIEF GROUP PLLC

NPI: 1376994608 · TAMPA, FL 33614 · Anesthesiology Physician · NPI assigned 06/28/2016

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official GARI, TRACIE controls 12+ related entities in our dataset. Read more

$1.90M
Total Medicaid Paid
190,181
Total Claims
119,044
Beneficiaries
54
Codes Billed
2019-09
First Month
2024-12
Last Month

Provider Details

Authorized OfficialGARI, TRACIE (CHIEF ADMINISTRATIVE OFFICER)
NPI Enumeration Date06/28/2016

Related Entities

Other providers sharing the same authorized official: GARI, TRACIE

ProviderCityStateTotal Paid
CHARLES K FRIEDMAN DO PA ST PETERSBURG FL $2.96M
WEST PARK SURGERY CENTER LLC PINELLAS PARK FL $2.37M
MEDICAL TOX LABS, LLC TAMPA FL $655K
TEXAS PAIN RELIEF GROUP PLLC HURST TX $507K
PHYSICIAN PARTNERS OF AMERICA CRNA OPERATIONS LLC HURST TX $349K
MEDHAT F. MIKHAEL, M.D., INC FOUNTAIN VALLEY CA $341K
SUN CITY CENTER AMBULATORY SURGERY CENTER, LLC RUSKIN FL $274K
MEDICAL DNA LABS, LLC TAMPA FL $107K
RICHARD L SMITH MD PA ORLANDO FL $74K
MERRITT ISLAND OUTPATIENT SURGERY CENTER, LLC MERRITT ISLAND FL $15K
HURST AMBULATORY SURGERY CENTER, LLC HURST TX $275.62
PAIN INSTITUTE OF TAMPA BAY, PLC TAMPA FL $0.00

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2019 472 $545.15
2020 12,477 $28K
2021 22,043 $428K
2022 49,912 $610K
2023 82,157 $511K
2024 23,120 $324K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 75,850 45,778 $901K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 37,609 25,388 $334K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 29,700 17,602 $324K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 3,116 2,061 $169K
64493 2,339 1,038 $42K
64494 2,610 1,020 $16K
95913 138 80 $12K
80358 1,911 1,314 $9K
80361 2,851 1,865 $8K
95886 204 67 $5K
80365 2,294 1,540 $5K
80332 894 690 $4K
80348 1,611 1,173 $4K
64483 193 103 $4K
83992 1,485 1,082 $4K
80370 1,170 801 $4K
80354 1,697 1,200 $4K
80356 2,177 1,407 $4K
80367 1,292 900 $4K
80324 2,153 1,403 $4K
80353 2,166 1,402 $4K
80335 853 670 $4K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 491 373 $3K
80373 1,175 878 $3K
80359 1,853 1,250 $3K
80360 1,392 964 $3K
80346 1,543 894 $3K
80362 802 506 $2K
80372 675 524 $2K
80364 1,185 743 $2K
80357 655 515 $2K
80368 562 369 $2K
64484 185 99 $1K
80369 453 354 $1K
64635 287 155 $1K
99215 Prolong outpt/office vis 56 29 $770.41
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 1,340 743 $609.31
80299 352 259 $478.18
99441 68 62 $474.56
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 206 150 $468.34
64495 40 33 $464.64
64636 289 157 $280.40
80305 27 24 $237.56
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 49 43 $201.44
62370 17 12 $91.75
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 25 17 $53.67
J1100 Injection, dexamethasone sodium phosphate, 1 mg 301 194 $31.26
64490 251 100 $0.00
J3490 Unclassified drugs 338 230 $0.00
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 704 498 $0.00
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg 208 137 $0.00
99442 33 31 $0.00
64491 275 101 $0.00
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 31 16 $0.00